ClinicalTrials.gg
TerminatedNCT05891197STARTUpdated Jul 1, 2025

A Biomarker Screening Protocol for Participants With Solid Tumors

An observational study in Triple Negative Breast Cancer, Non-small Cell Lung Cancer and Non Small Cell Lung Cancer, sponsored by Lyell Immunopharma, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-07-01.

Primary conditionnone(registry's first term: Triple Negative Breast Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Triple Negative Breast Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Lyell Immunopharma, Inc. · Observational

How we know

Why this study was terminated
Pipeline Reprioritization

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
10
Ages
18 Years to 99 Years
Sex
All
01

Study summary

Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease indications and tumor expression of target(s) of interest that may inform eligibility for active and future Lyell clinical trials. No investigational treatments will be administered in this non-interventional screening study. Only previously obtained archival tumor tissue will be allowed on this study for biomarker analysis. Fresh tumor biopsies are not permitted on this study. The study will be conducted virtually and participants will utilize telehealth and e-consent modules. If participants tumors express the biomarkers of interest they can be referred to open and enrolling clinical trials. Participation on the screening study does not guarantee enrollment or treatment on an interventional clinical trial.

02

Conditions studied

  • Triple Negative Breast Cancer
  • Non-small Cell Lung Cancer
  • Non Small Cell Lung Cancer
  • Non Small Cell Lung Cancer Metastatic
  • Non-Small Cell Carcinoma of Lung, TNM Stage 4
  • Advanced Breast Cancer
  • Advanced Lung Carcinoma
  • NSCLC
  • NSCLC, Recurrent
  • NSCLC Stage IV
  • Relapsed Cancer
  • Relapse/Recurrence
  • Recurrent Breast Cancer
  • Recurrent NSCLC
  • Platinum-resistant Ovarian Cancer
  • Ovarian Cancer
  • Primary Peritoneal Carcinoma
  • Fallopian Tube Cancer
  • Endometrial Cancer
  • Endometrioid Tumor
  • High Grade Serous Carcinoma
  • Ovarian Epithelial Cancer

Keywords

  • Biomarker Screening
  • Immunotherapy
  • CAR-T
  • CAR T-cell therapy
  • CAR T
  • CAR T-cell
  • ROR1
  • ROR1+
  • ROR1 positive
  • cell therapy
  • relapsed
  • refractory
  • solid tumor
  • advanced
  • metastatic
  • breast cancer
  • lung cancer
  • triple negative breast cancer
  • non small cell lung cancer
  • ovarian cancer
  • endometrial cancer
03

In context

Lead sponsor

Lyell Immunopharma, Inc. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults 18 years of age or older with histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumor malignancy who are willing to have archival tumor tissue analyzed for biomarker(s).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged ≥ 18 years at time of
  2. Able to provide informed consent
  3. or cytologically confirmed diagnosis of advanced or solid tumor .The Sponsor will indicate which solid tumor disease indications are open to enrollment.
  4. Ability to provide a tumor tissue sample collected within 3 years prior to enrollment. The sample must consist, at minimum, of 5 freshly cut, unstained 4-5 μM sections cut from a formalin-fixed paraffin-embedded (FFPE) tissue block. The sample must contain sufficient tumor tissue to allow for the evaluation of biomarker expression

Exclusion criteria

Exclusion Criteria:

  1. Prior solid organ transplantation
  2. Prior treatment with any adoptive cell therapy
  3. Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with a clinical study, as judged by the Investigator or Sponsor's Medical Monitor
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
10 participants (actual)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. To identify participants whose tumors express biomarkers, such as ROR1, that may inform eligibility for active and future Lyell clinical trials

    Time frame: 5 years

Secondary outcomes

  1. To explore tumor expression of biomarkers, such as ROR1, by different methods (e.g., IHC versus next-generation sequencing [NGS])

    Time frame: 5 years

07

Study locations

1 site
  • Accellacare
    Rocky Mount, North Carolina 27804, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Feb 2025, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2023
First posted
Jun 6, 2023
StartActual
May 19, 2023
Primary completionActual
Feb 5, 2025
CompletionActual
Feb 5, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05891197
Lead sponsor
Lyell Immunopharma, Inc.
Collaborators
ICON plc
Responsible party
Sponsor
First posted
Jun 6, 2023
Start date
May 19, 2023
Primary completion
Feb 5, 2025
Completion
Feb 5, 2025
Last update
Jul 1, 2025

Study contacts

Jackie Walling, MBChB, PhD
study chair · Lyell Immunopharma

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion